Show simple item record

dc.contributor.authorZinzani, P
dc.contributor.authorSasse, S
dc.contributor.authorRadford, John A
dc.contributor.authorGautam, A
dc.contributor.authorBonthapally, V
dc.date.accessioned2016-08-10T10:05:50Z
dc.date.available2016-08-10T10:05:50Z
dc.date.issued2016-08
dc.identifier.citationBrentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. 2016, 104:65-70 Crit Rev Oncol Hematolen
dc.identifier.issn1879-0461
dc.identifier.pmid27279289
dc.identifier.doi10.1016/j.critrevonc.2016.04.019
dc.identifier.urihttp://hdl.handle.net/10541/618151
dc.description.abstractBrentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in ∼60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N=480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL.
dc.language.isoenen
dc.rightsArchived with thanks to Critical reviews in oncology/hematologyen
dc.titleBrentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.en
dc.typeArticleen
dc.contributor.departmentInstitute of Hematology and Medical Oncology, 'L. & A. Seragnoli', University of Bologna, Bologna, Italyen
dc.identifier.journalCritical Reviews in Oncology/Hematologyen
dc.description.collectionLymphoma Research Teamen
refterms.dateFOA2018-12-17T14:36:38Z
html.description.abstractBrentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in ∼60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N=480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL.


Files in this item

Thumbnail
Name:
PIIS1040842816301056.pdf
Size:
460.2Kb
Format:
PDF
Description:
Open access full text article

This item appears in the following Collection(s)

Show simple item record